MANE - Company ID 0001827635
Veradermics, Inc trades as MANE and has a market capitalization of $5.17 B, making it the #1392 largest US-listed company by market value. This page tracks Veradermics, Inc through 73 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| D | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-12 |
| Major company event | 8-K | 2026-05-12 |
| SCHEDULE 13G | - | 2026-05-07 |
| SCHEDULE 13D/A | - | 2026-05-05 |
| SCHEDULE 13D | - | 2026-05-05 |
| New insider ownership | 3 | 2026-05-05 |
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that topline results from Phase 2/3 ‘302’ Study of VDPHL01 will be presented at the 2026 World Congress for Hair Research on May 30, 2026 .
The data to be presented include two comparative analyses of VDPHL01's Phase 2 male data results versus published data on the efficacy of existing minoxidil formulations. The first is a blinded, retrospective investigator global assessment in which nine independent dermatologists evaluated the perceived efficacy of VDPHL01 at 2 and 4 months in males against 6-month male data on immediate-release oral minoxidil and topical minoxidil. The second leverages Global HairMap™ (SOCAi), an AI-based platform, to retrospectively compare androgenetic alopecia (AGA) outcomes of VDPHL01 at 4 months against males receiving immediate-release oral minoxidil for 6 months.
Positive topline results from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first FDA-approved oral treatment for pattern hair loss in nearly 30 years
Jefferies, Leerink Partners , Citigroup, and Cantor are acting as joint bookrunning managers for the offering. LifeSci Capital is acting as passive bookrunner for the offering. Needham & Company is acting as lead manager for the offering. Jefferies, Leerink Partners , Citigroup, Cantor, LifeSci Capital and Needham & Company are acting as placement agents in connection with the private placement.
Veradermics, Incorporated (“Veradermics”) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that it has launched a proposed public offering of 3,350,000 shares of common stock (and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock) pursuant to a registration statement filed on Form S-1 with the Securities and Exchange Commission (“SEC”). All of the shares and pre-funded warrants are being offered by Veradermics. In addition, the underwriters are expected to have a 30-day option to purchase up to an additional 502,500 shares of common stock at the public offering price, less underwriting discounts and commissions, solely with respect to shares of common stock and pre-funded warrants sold in the public offering. Veradermics expects to enter into a securities purchase agreement substantially concurrently with the of
The largest companies sharing Veradermics, Inc's SEC industry classification (pharmaceutical preparations).
Veradermics, Inc (MANE) has a market capitalization of $5.17 B as of 2026-07-09, ranking #1392 among US-listed companies.
In its latest fiscal year Veradermics, Inc reported a net loss of $70.00M.